AstraZeneca Pharma India to Launch Eculizumab (Soliris) in August 2025 for Rare Disease Treatment

Image Source : Pharma Industrial India

AstraZeneca Pharma India Ltd is set to launch Eculizumab, marketed as Soliris, in August 2025 following regulatory approval from the Central Drugs Standard Control Organisation (CDSCO). This marks a major milestone in India’s rare disease treatment landscape, as Eculizumab becomes the first anti-complement therapy approved for managing two life-threatening conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS).

The launch is expected to significantly improve access to advanced biologic therapies for patients suffering from these debilitating disorders, many of whom previously had limited or no treatment options.

Key Highlights from the Announcement

- AstraZeneca received CDSCO approval under Form CT-20 to import, sell, and distribute Eculizumab concentrate for infusion (300 mg, 10 mg/ml)
- The drug is indicated for both adult and pediatric patients diagnosed with PNH and aHUS
- Eculizumab will be available in India starting August 2025, subject to final statutory clearances

Clinical Significance and Therapeutic Scope

Eculizumab is a monoclonal antibody that inhibits the complement protein C5, preventing the formation of the membrane attack complex responsible for cell destruction in complement-mediated diseases.

1. Paroxysmal Nocturnal Hemoglobinuria (PNH)
- A rare, acquired blood disorder characterized by chronic hemolysis, thrombosis, and organ damage
- Without treatment, patients face high mortality rates and severe complications such as renal failure and stroke
- Eculizumab has shown to reduce hemolysis, improve quality of life, and significantly lower thrombotic events

2. Atypical Hemolytic Uremic Syndrome (aHUS)
- A genetic or acquired condition marked by thrombotic microangiopathy, acute kidney injury, and neurological symptoms
- Eculizumab helps prevent complement-mediated damage, reducing hospitalizations and long-term organ impairment

Strategic Context and Portfolio Expansion

The launch of Eculizumab in India is part of AstraZeneca’s broader strategy to expand its rare disease portfolio following its acquisition of Alexion Pharmaceuticals in 2021.

- Alexion pioneered complement biology and developed Soliris as a first-in-class therapy for complement-mediated diseases
- AstraZeneca aims to build on this legacy by introducing more rare disease treatments in India, including therapies for neurology and metabolic disorders
- The company is also investing in physician education and diagnostic infrastructure to support early identification and treatment of rare conditions

Market Impact and Patient Access

The availability of Eculizumab in India is expected to transform the treatment landscape for rare diseases:

- Patients previously dependent on off-label or imported therapies will now have access to a globally approved standard of care
- AstraZeneca plans to collaborate with hospitals, insurance providers, and government programs to improve affordability and access
- The launch aligns with India’s National Policy for Rare Diseases, which emphasizes early diagnosis and equitable treatment access

Regulatory and Commercial Milestones

- CDSCO approval was granted in January 2025, following a rigorous review of safety, efficacy, and global clinical data
- Eculizumab is already approved in over 60 countries and has generated over $3 billion in global revenue in FY23
- AstraZeneca will distribute the drug through select tertiary care centers and specialty pharmacies across India

Looking Ahead: Commitment to Rare Disease Innovation

AstraZeneca Pharma India is expected to focus on:

1. Expanding its rare disease pipeline with therapies targeting neuromuscular and metabolic disorders
2. Enhancing diagnostic capabilities through partnerships with genetic testing labs and academic institutions
3. Supporting patient advocacy groups to raise awareness and improve treatment literacy
4. Building a sustainable access model through pricing strategies and public-private collaborations

Conclusion

The upcoming launch of Eculizumab (Soliris) by AstraZeneca Pharma India in August 2025 marks a transformative moment for rare disease care in the country. With CDSCO approval in place and a robust distribution strategy, the company is poised to deliver life-saving therapy to patients with PNH and aHUS. This initiative not only strengthens AstraZeneca’s presence in India’s specialty care market but also reflects its commitment to pioneering science and patient-first innovation.

Sources: AstraZeneca India Press Release, Economic Times Pharma, Business Standard, BW Healthcare World